Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase NA 1Phase 3 1Phase 2 1

Status

Unknown 5Completed 5Recruiting 4Terminated 2Not yet recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 5

Conditions

Breast Neoplasms 37Advanced Breast Cancer 5Neoplasm Metastasis 4Neoplasms 2The Neoadjuvant Therapy 1Solid Tumor, Adult 1Recurrent Uterine Corpus Carcinoma 1Hormone Receptor-positive Advanced Breast Cancer 1Hormone Receptor Positive Advanced Breast Cancer 1HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer 1HR Positive/HER-2 Negative Breast Cancer 1Estrogen Receptor-positive Breast Cancer 1Carcinoma, Intraductal, Noninfiltrating 1Carcinoma, Ductal, Breast 1Breast Neoplasm Female 1Breast Diseases 1Breast Carcinoma In Situ 1Breast Cancer Organoids 1Brain Neoplasms 1

Interventions

Fulvestrant 5Letrozole 4Capecitabine 3pyrotinib 2Paclitaxel 2Goserelin 2Anastrozole 2palbociclib 1olaparib 1neratinib 1liposomal doxorubicin 1exemestane 1entinostat 1ceralasertib 1capivasertib 1Vinorelbine 1Trastuzumab 1Standard of Care 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Injections 1In Situ Hybridization, Fluorescence 1Immunotherapy, Adoptive 1Gonadotropin-Releasing Hormone 1FCN-437c 1Docetaxel 1Decitabine 1Cyclophosphamide 1Combined Modality Therapy 1Cisplatin 1CYH33 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Unknown × Advanced Breast Cancer × Fulvestrant × Clear all
NCT06047184 2023-09-21

Phase I Study of BEBT-209 in Women With Advanced Breast Cancer

BeBetter Med Inc

Phase 1 Unknown
106 enrolled
Breast

Advanced Breast Cancer

NCT05047848 2021-09-17

Clinical Study of Chidamide Combined With Fulvestrant in the Treatment of Hormone Receptor-positive Advanced Breast Cancer

Liaoning Cancer Hospital & Institute

Phase NA Unknown
82 enrolled
Breast

Advanced Breast Cancer

NCT03927456 2021-06-03

A Study of SHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Unknown
357 enrolled
Breast

Advanced Breast Cancer

NCT04856371 2021-04-23

Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast Cancer

Haihe Biopharma Co., Ltd.

Phase 1 Unknown
228 enrolled
Breast

Advanced Breast Cancer

NCT03182634 2019-01-22

plasmaMATCH

Institute of Cancer Research, United Kingdom

Phase 2 Unknown
1,150 enrolled
Breast

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡